4.5 Article

Human Microdosing with Carcinogenic Polycyclic Aromatic Hydrocarbons: In Vivo Pharmacokinetics of Dibenzo[def,p]chrysene and Metabolites by UPLC Accelerator Mass Spectrometry

期刊

CHEMICAL RESEARCH IN TOXICOLOGY
卷 29, 期 10, 页码 1641-1650

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acs.chemrestox.6b00169

关键词

-

资金

  1. PHS [P42ES016465, P42ES016465-S1, P41GM103483, P01CA90890, T32ES07060]
  2. U.S. Department of Energy [DE-AC52-07NA27344]
  3. National Institute of General Medical Sciences, Biomedical Technology Research Resources (BTRR) [P41GM103483]

向作者/读者索取更多资源

Metabolism is a key health risk factor following exposures to pro-carcinogenic polycyclic aromatic hydrocarbons (PAHs) such as dibenzo[def,p]chrysene (DBC), an IARC classified 2A probable human carcinogen. Human exposure to PAHs occurs primarily from the diet in nonsmokers. However, little data is available on the metabolism and pharmacokinetics in humans of high molecular weight PAHs (>= 4 aromatic rings), including DBC. We previously determined the pharmacokinetics of DBC in human volunteers orally administered a microdose (29 ng; 5 nCi) of [C-14]-DBC by accelerator mass spectrometry (AMS) analysis of total [C-14] in plasma and urine. In the current study, we utilized a novel moving wire interface between ultraperformance liquid chromatography (UPLC) and AMS to detect and quantify parent DBC and its major metabolites. The major [C-14] product identified in plasma was unmetabolized [C-14]-DBC itself (C-max = 18.5 +/- 15.9 fg/mL, T-max= 2.1 +/- 1.0 h), whereas the major metabolite was identified as [C-14]-(+/)-DBC-11,12-diol (C-max= 2.5 +/- 1.3 fg/mL, T-max= 1.8 h). Several minor species of [C-14]-DBC metabolites were also detected for which no reference standards were available. Free and conjugated metabolites were detected in urine with [C-14]-(+/)-DBC-11,12,13,14-tetraol isomers identified as the major metabolites, 56.3% of which were conjugated (C-max= 35.8 +/- 23.0 pg/pool, T-max = 6-12 h pool). [C-14]-DBC-11,12-diol, of which 97.5% was conjugated, was also identified in urine (C-max = 29.4 +/- 11.6 pg/pool, T-max = 6-12 h pool). Parent [C-14]-DBC was not detected in urine. This is the first data set to assess metabolite profiles and associated pharmacokinetics of a carcinogenic PAH in human volunteers at an environmentally relevant dose, providing the data necessary for translation of high dose animal models to humans for translation of environmental health risk assessment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据